Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Study sponsor: Palvella Therapeutics, Inc. · PVLA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-11-15Actual
Enrollment · participants12Actual
Source updated2025-01-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.